Graft Polymer (UK) PLC ( (GB:SVNS) ) just unveiled an update.
Solvonis Therapeutics plc announced a significant advancement in its AWKN-SDN-14 programme, a collaboration with Awakn Life Sciences Corp. aimed at developing next-generation treatments for trauma-related mental health disorders. The European Patent Office has deemed the claims under their European Patent Application as allowable, reinforcing the programme’s intellectual property position in Europe. This development is a crucial step in Solvonis’s broader international patent strategy and underscores the scientific and commercial potential of their core compounds as they move towards clinical development.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders. The company co-develops therapeutics for mental health disorders, with a particular focus on trauma-related conditions such as PTSD, which affects millions in the U.S., UK, and key EU markets.
YTD Price Performance: -14.00%
Average Trading Volume: 11,292,740
Technical Sentiment Signal: Buy
Current Market Cap: £4.02M
Find detailed analytics on SVNS stock on TipRanks’ Stock Analysis page.